文献速递炎症性肠病

古塞奇尤单抗治疗克罗恩病和溃疡性结肠炎的真实世界前瞻性研究

Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-22

该前瞻性研究纳入234例 iniciando 古塞奇尤单抗的成人IBD患者(142例CD,92例UC),随访至52周。第12周CD临床缓解率76.8%,UC为80.7%;基线活动期患者缓解率CD 58.5%、UC 72.9%。不良反应发生率6.4%,多为轻度。

要点

  • 古塞奇尤单抗在真实世界中第12周诱导CD和UC临床缓解率分别为76.8%和80.7%。
  • 基线活动期患者第12周缓解率较低:CD 58.5%,UC 72.9%。
  • 不良反应发生率6.4%,多为轻度,7例因不良反应停药。

核心结论

  • 古塞奇尤单抗在真实世界IBD患者中诱导和维持了较高的临床缓解率,安全性特征与关键试验相似。

研究设计与样本

  • 前瞻性真实世界研究,纳入2024年9月至2026年1月单中心 iniciando 古塞奇尤单抗的成人IBD患者234例(CD 142例,UC 92例),随访至52周。

主要发现

  • 第12周临床缓解率CD为76.8%(HBI<5),UC为80.7%(SCCAI≤2)。
  • 基线活动期患者第12周缓解率CD为24/41(58.5%),UC为35/48(72.9%)。
  • 第6个月维持缓解率CD为88.4%,UC为85.4%。
  • 第12周CRP正常率CD为72.9%,UC为90.0%。
  • 不良反应发生15例(6.4%),多为轻度,7例因不良反应停药。

关键数值与推荐

  • 临床缓解定义:CD为Harvey-Bradshaw指数(HBI)<5,UC为简单临床结肠炎活动指数(SCCAI)≤2。

临床怎么用

  • 古塞奇尤单抗可用于中重度活动性CD和UC的真实世界治疗,需关注基线活动期患者诱导期缓解率相对较低。

局限性

  • 单中心前瞻性研究,样本量有限,随访时间最长52周,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Guselkumab (GUS), selective IL-23p19 inhibitor that also binds to CD64+ cells, is approved for the treatment of moderately-to-severely active Crohn's disease (CD) and ulcerative colitis (UC). Real-world evidence of effectiveness and safety is needed. METHODS: We prospectively enrolled adult patients with IBD initiating GUS at our tertiary center between 9/2024 and 1/2026. Patients were followed for up to 52 weeks. Clinical and biochemical data were collected at designated time points on patients' activity indices and adverse events (AEs). Clinical remission was defined as a Harvey-Bradshaw Index (HBI) <5 for CD or Simple Clinical Colitis Activity Index (SCCAI) ≤2 for UC. RESULTS: We followed 234 patients who initiated GUS (142 CD, 92 UC). Week 12 clinical remission was achieved in 76.8% of patients with CD (HBI<5) and 80.7% of patients with UC (SCCAI≤2). Among patients with active disease at baseline, week 12 remission rates were 24/41 (58.5%) in CD and 35/48 (72.9%) in UC. Remission was maintained at month 6 in 88.4% in CD. In UC, remission rates at 6 months were maintained in 85.4% of patients. Normal CRP at week 12 was observed in 72.9% patients with CD and 90.0% in UC. Disease location, extent, or behavior were not associated with different response rates. AEs occurred in 15 patients (6.4%) and were mostly mild; 7 patients discontinued GUS due to AEs. CONCLUSION: In this large real-world prospective experience of GUS for IBD, we describe high rates of remission and an overall safety profile that is similar to that seen in the pivotal trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shafrir A, Choi D, Capucci LC, et al. Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study. Clin Gastroenterol Hepatol. 2026. PMID: 42913902. doi:10.1016/j.cgh.2026.09.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。